BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $1.28B
• Dividend Yield: N/A
• Average Volume (3M): 367.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: -18.82%
• EPS Growth: 92.56%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.01
• Shares Outstanding: 48,148,045
• 10 Day Avg. Volume: 439,560
• 30 Day Avg. Volume: 367,774
• PEG Ratio: 0.83
• Price to Book (P/B): 3.43
• Price to Sales (P/S): 14.54
• P/FCF Ratio: 229.80
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 16.01
• Enterprise Value/Gross Profit: 19.99
• Enterprise Value/Ebitda: -243.21
• 1Y Price Target: $32.29
• Price Target Upside: 21.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): $96.81M

• Rating: 54 Neutral
• Price Target: $26.00 ▼(-1.89% Downside)

BioLife Solutions' overall stock score is driven by a mix of financial challenges and positive earnings call insights. The company's financial performance is hindered by declining revenues and profitability, but it benefits from a strong gross profit margin and conservative leverage. Technical analysis indicates mixed signals, with short-term bearish momentum but longer-term support. Valuation is a weak point due to significant losses and no dividend yield. However, the positive sentiment from the earnings call, highlighting strong revenue growth and strategic focus, provides a counterbalance, resulting in a moderate overall score.

Positive Factors

Revenue Growth

The significant growth in cell processing revenue indicates strong demand for BioLife's products, suggesting robust market positioning and potential for sustained revenue expansion.

Market Leadership

BioLife's high market share in approved therapies and clinical trials underscores its competitive advantage and leadership in the biopreservation sector, supporting long-term business stability.

Improved Profitability

The improvement in EBITDA margin reflects enhanced operational efficiency, indicating a scalable business model that can drive future profitability.

Negative Factors

Declining Revenue

The decline in revenue growth poses a challenge to financial health, potentially impacting long-term sustainability if not addressed.

Increased Operating Expenses

Rising operating expenses could pressure margins and profitability, necessitating cost management to maintain financial stability.

Adjusted Gross Margin Decline

The decline in gross margin may indicate challenges in maintaining cost efficiency, potentially affecting long-term profitability.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

How the Company Makes Money

BioLife Solutions generates revenue primarily through the sale of its biopreservation products and services to a diverse range of customers, including pharmaceutical companies, research institutions, and clinical laboratories involved in cell and gene therapy. Key revenue streams include direct sales of its proprietary media and cryopreservation solutions, as well as recurring revenue from long-term contracts with customers for product supply. The company also benefits from strategic partnerships with biotech firms and research organizations that enhance its market reach and product development capabilities. Additionally, BioLife Solutions may see increased earnings through collaborations that expand its product offerings and enter new markets, capitalizing on the growing demand for biopreservation solutions in the rapidly evolving life sciences sector.

BioLife Solutions Financial Statement Overview

Summary

BioLife Solutions faces challenges with declining revenues and profitability, as evidenced by negative net profit margins and ROE. Despite these issues, the company maintains a strong gross profit margin and a conservative leverage position. Cash flow generation is moderate, but the decline in free cash flow growth is a concern. Overall, the company needs to address its profitability and revenue growth to improve its financial health.

Income Statement

BioLife Solutions has experienced declining revenue over the TTM period, with a negative revenue growth rate of -3.27%. The company shows a strong gross profit margin of 81.42%, indicating efficient cost management. However, the net profit margin is negative at -7.23%, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, suggesting operational challenges.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.069, indicating conservative leverage. However, the return on equity is negative at -1.61%, highlighting profitability issues. The equity ratio is relatively stable, suggesting a solid capital structure despite the negative ROE.

Cash Flow

The cash flow statement reveals a decline in free cash flow growth of -7.74% over the TTM period. The operating cash flow to net income ratio is 0.55, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is 0.74, showing some ability to convert earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	74.00M	82.25M	143.27M	76.24M	119.16M	48.09M
Gross Profit	59.27M	53.67M	46.75M	53.82M	37.75M	27.44M
EBITDA	-4.87M	1.53M	-45.24M	-124.18M	-16.65M	1.48M
Net Income	-3.21M	-20.18M	-66.43M	-139.81M	-8.91M	2.67M
Balance Sheet
Total Assets	392.08M	399.49M	412.71M	450.23M	552.60M	234.83M
Cash, Cash Equivalents and Short-Term Investments	78.95M	104.58M	44.18M	62.70M	69.87M	90.46M
Total Debt	20.68M	30.17M	33.83M	43.71M	26.88M	11.15M
Total Liabilities	38.34M	50.58M	75.05M	86.04M	71.85M	29.58M
Stockholders Equity	353.74M	348.91M	337.66M	364.19M	480.75M	205.25M
Cash Flow
Free Cash Flow	10.56M	5.20M	-18.88M	-18.87M	-13.22M	1.88M
Operating Cash Flow	16.84M	8.43M	-12.50M	-8.49M	-4.84M	6.51M
Investing Cash Flow	961.00K	58.30M	17.84M	-58.12M	-12.64M	-23.73M
Financing Cash Flow	-4.09M	-6.78M	10.59M	16.32M	-2.78M	102.08M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Positive. The current price of 26.5 is above the 20-day moving average (MA) of 26.03, above the 50-day MA of 26.44, and above the 200-day MA of 24.32, indicating a bullish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 52.47 is Neutral, neither overbought nor oversold. The STOCH value of 87.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KMTS	58 Neutral	$1.39B	-10.69	―	―	83.78%	-25.37%
AZTA	56 Neutral	$1.38B	-12.40	1.37%	―	-9.49%	56.22%
BLFS	54 Neutral	$1.28B	―	-5.20%	―	-18.82%	92.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	49 Neutral	$1.32B	―	-24.65%	―	-32.42%	-540.37%
PLSE	44 Neutral	$927.74M	-12.06	-86.99%	―	―	-40.63%
SMTI	41 Neutral	$186.93M	―	-27.19%	―	30.55%	-340.19%

BioLife Solutions Corporate Events

BioLife Solutions Reports Strong Q3 Earnings Growth

BioLife Solutions Inc has reported a positive sentiment in its latest earnings call, showcasing strong revenue growth and improved profitability. The company has made strategic moves, such as the sale of the evo Cold Chain product line, to bolster its financial position. Despite some challenges, including a decline in adjusted gross margin and increased operating expenses, the overall outlook remains optimistic due to robust growth metrics and a strategic focus on core competencies.

BioLife Solutions Reports Strong Q3 2025 Growth

BioLife Solutions Inc., a prominent player in the cell and gene therapy market, specializes in developing and supplying cell processing tools and services that ensure the viability of biologic materials throughout their lifecycle.

BioLife Solutions Holds Annual Stockholders Meeting

On August 20, 2025, BioLife Solutions, Inc. conducted its annual meeting of stockholders, where key decisions were made. The stockholders re-elected seven directors, approved executive compensation on a non-binding basis, and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (BLFS) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.

BioLife Solutions Reports Strong Q2 Growth Amid Challenges

BioLife Solutions Inc. recently held its Q2 2025 earnings call, showcasing a mixed sentiment among stakeholders. The company reported significant revenue growth and increased guidance, reflecting strong operational performance and future potential. However, the overall financial results were tempered by increased operating expenses and net loss, primarily due to noncash charges. Despite these challenges, BioLife’s robust cash position and strategic investments suggest a promising outlook for future growth.

BioLife Solutions Reports Strong Q2 2025 Growth

BioLife Solutions Inc., a prominent player in the cell and gene therapy market, specializes in developing and supplying cell processing tools and services. The company is recognized for its biopreservation media and other innovative solutions that support the commercialization of new therapies.